C1-esterase inhibitor on systemic inflammation in trauma patients with femur or pelvic fracture
Trauma · Inflammation · Sepsis · Multiple Organ Dysfunction Syndrome
Enrolment: 11 · Results not recorded
Loading the evidence…
Biologic · EXOGENOUS PROTEIN; recombinant human C1 esterase inhibitor replaces deficient plasma protease C1 inhibitor, restraining activation of the classical complement and contact (kallikrein-kinin) pathways. mec_id 9807, direct_interaction true, disease_efficacy true, ATC B06AC04, EMA Ruconest.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Trauma · Inflammation · Sepsis · Multiple Organ Dysfunction Syndrome
Enrolment: 11 · Results not recorded
Hereditary Angioedema Types I and II
Enrolment: 46 · Results not recorded
Hereditary Angioedema
Enrolment: 146 · Results not recorded
Genetic Disorders
Enrolment: 14 · Results not recorded
Kidney Transplant
Enrolment: 180 · Results not recorded
Genetic Disorders
Enrolment: 14 · Results not recorded
Hereditary Angioedema Type I · Angioneurotic Edema
Enrolment: 12 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Dorsal full-thickness burn wounds measuring 2 x 4 cm
C1 esterase inhibitor treatment significantly reduced granulation tissue and macrophage infiltration and increased reepithelialisation in burn wounds. It also counteracted burn-induced macrophage infiltration into the ventricles and atria of the heart.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.